Libido Enhancement

Overview

Low libido affects both men and women and has complex multifactorial causes including hormonal imbalance, stress, relationship factors, and neurochemical dysregulation. Peptides for libido enhancement act centrally on desire circuits (melanocortin, oxytocin) and peripherally via the HPG axis. PT-141 is FDA-approved specifically for Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women.

Recommended Peptides

PT-141 (Bremelanotide) – FDA-approved for HSDD in women; acts on MC4 receptors in the hypothalamus to increase sexual desire independently of hormonal status; also effective in men for desire (separate from erection); on-demand dosing
Kisspeptin-10 – upstream HPG axis activator; increases LH/FSH and downstream sex hormones; studied for sexual desire and attraction responses; may normalize hormonal contributions to low libido
Oxytocin – intranasal oxytocin enhances sexual desire, arousal, and intimacy; particularly useful for relationship and bonding dimensions of low libido
Melanotan II – potent but non-selective; strong pro-libido effects in both sexes; higher side effect profile limits use as first-line

Protocols

Sexual Health Protocol

Related Conditions

Research Summary

PT-141 (bremelanotide/Vyleesi) is FDA-approved for HSDD in premenopausal women. RECONNECT Phase 3 trials (n=1,267) demonstrated significant improvements in sexual desire and reduced distress (PMID-31599840). The melanocortin mechanism acts centrally via MC4R to increase dopamine in the mPOA (PMID-33455598). Kisspeptin increased penile tumescence 56% over placebo in men with HSDD (PMID-36735255).

#condition #reproductive